-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SRA-515 in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SRA-515 in Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SRA-515 in Lymphoma Drug Details:SRA-515 is under development for the treatment of solid tumors...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Aceclidine + Brimonidine) in Presbyopia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (Aceclidine + Brimonidine) in Presbyopia Drug Details: LNZ-101 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cobimetinib Fumarate in Pediatric Diffuse Intrinsic Pontine Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cobimetinib Fumarate in Pediatric Diffuse Intrinsic Pontine Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Cobimetinib Fumarate in Pediatric Diffuse Intrinsic Pontine GliomaDrug Details:Cobimetinib...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SRA-515
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SRA-515 Drug Details SRA-515 is under development for the treatment of solid tumors including...
-
Sector Analysis
UK Personal Injury Litigation 2017
"UK Personal Injury Litigation 2017", report is an in-depth study into the claims landscape of the personal injury market, which covers motor, employers’ liability, public liability, and clinical negligence. It explores the change in claims numbers over time and in relation to reforms such as LASPO. It also discusses upcoming regulatory changes such as the Civil Liability Bill and the discount rate, and the future impact these will have in the personal injury space. The role of CMCs and solicitors...
-
Sector Analysis
UK Personal Injury Litigation 2016; The turbulent course of market-changing reform continues
The personal injury sector continues its turbulent course of market-changing reform, with legislative, legal, and regulatory forces at work. While the market was just beginning to settle post-Legal Aid, Sentencing and Punishment of Offenders Act 2012 (LASPO), the game-changing reforms announced by the government in November 2015 have once again whipped up a storm of uncertainty.